Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Applying proteomic technology to clinical virology.

Authors
Type
Published Article
Journal
Clinical Microbiology and Infection
1469-0691
Publisher
Elsevier
Publication Date
Volume
19
Issue
1
Pages
23–28
Identifiers
DOI: 10.1111/1469-0691.12029
PMID: 23034105
Source
Medline
License
Unknown

Abstract

Developing antiviral drugs, vaccines and diagnostic markers is still the most ambitious challenge in clinical virology. In the past few decades, data from high-throughput technologies have allowed for the rapid development of new antiviral therapeutic strategies, thus making a profound impact on translational research. Most of the current preclinical studies in virology are aimed at evaluating the dynamic composition and localization of the protein platforms involved in various host-virus interactions. Among the different possible approaches, mass spectrometry-based proteomics is increasingly being used to define the protein composition in subcellular compartments, quantify differential protein expression among samples, characterize protein complexes, and analyse protein post-translational modifications. Here, we review the current knowledge of the most useful proteomic approaches in the study of viral persistence and pathogenicity, with a particular focus on recent advances in hepatitis C research.

Statistics

Seen <100 times